Clinical trial · Interventional
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Evaluation of the Effectiveness of Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT Study).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
EMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) study is a randomized, multi-center, placebo-controlled, double-blind trial to evaluate efficacy of empagliflozin in prevention of left ventricular (LV) dysfunction in patients receiving high cumulative doses of anthracyclines. Diagnosed with cancer, 220 patients without history of heart failure and LV ejection fraction (EF) ≥ 50%, scheduled for high dose anthracyclines (doxorubicin ≥240 mg/m2 or epirubicin ≥540 mg/m2), will be included in the study. They will be randomized to a 10 mg of empagliflozin once daily or to matching placebo in a 1:1 ratio. The primary objective of the EMPACT study is to assess whether prophylactic SGLT-2 inhibitors may prevent a reduction in LVEF after high doses anthracyclines, as evaluated by serial echocardiography on each visit and cardiovascular magnetic resonance (CMR) performed at randomization and on its completion. The secondary composite endpoint includes: all-cause death, cardiovascular (CV) death, myocardial infarction and ischemic stroke. Additional secondary outcome measures include structural myocardial alterations assessed by CMR, decrease in GLS (global longitudinal strain) in echocardiography and changes in cardiac biomarkers. The study will be carried out in accordance with GCP and monitoring will be outsourced to a subcontractor - CRO. The examination will be insured and will begin as soon as the required approvals are obtained.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Empagliflozin 10 MG | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Empagliflozin
- description
- Empagliflozin, 10 mg q.d; p.o
- interventionNames
- Drug: Empagliflozin 10 MG
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo 1 tabl q.d; p.o
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Number of participants with diagnosis of cancer treatment-related cardiac dysfunction (CTRCD) at any time over the 12-month study period
- timeFrame
- from date of randomization until 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
The study will include patients with diagnosed cancer, diagnosed and qualified for further systemic treatment at the National Institute of Oncology in Warsaw. Patients must give informed and voluntary consent to participate in the study and meet all the conditions for inclusion in the study Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2. 2. Age ≥18 years at the time of signing the informed consent. 3. Known neoplastic disease prior to the initiation of chemotherapy with a high dose of anthracyclines (doxorubicin ≥ 240 mg / m2 b.w. or epirubicin ≥ 540 mg / m2 b.w.) 4. No history of heart failure (left ventricular ejection fraction ≥ 50% as assessed by echocardiography). 5. Women of child-bearing age must have a negative serum or urine pregnancy test. 6. All males and females must consent to the use of effective contraception throughout the study period and after study medication is discontinued. 7. Sexually active women of childbearing potential must use 2 effective methods of contraception (abstinence, IUD, oral contraceptive or double barrier device) from informed consent and for at least 6 months after study drug discontinuation 8. Sexually active men and their sexual partners must use effective methods of contraception from the moment they sign their informed consent to participate in the study and for at least 3 months after discontinuation of the study drug. Exclusion Criteria: 1. History of heart failure 2. Left ventricle systolic dysfunction assessed by echocardiography (LVEF \<50%) 3. Significant valve disease 4. Previous chemotherapy or radiation to the chest 5. Symptomatic hypotension and / or SBP \<100 mmHg at Visit 1 or Visit 2 6. Liver disease, as determined by ALT, AST, or alkaline phosphatase levels above 3 x upper limit of normal (ULN) at visit 1. 7. Renal impairment, defined as eGFR \<20 mL / min / 1.73 m2 or dialysis requirement, as determined at Visit 1. 8. History of ketoacidosis 9. Gastrointestinal surgery or gastrointestinal disturbance that could impair drug absorption 10. Presence of any disease with a life expectancy \<1 year in the opinion of the investigator. 11. Treatment with any SGLT-2 inhibitor for up to 3 months prior to study enrollment. 12. Pregnancy or breastfeeding 13. Drug or alcohol abuse 14. Suspected non-compliance and irregular use of study drug 15. Inability to perform CMR, e.g. claustrophobia, weight\> 120 kg, etc.
References
Publications (0)
Data not yet available